Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

NCT00502788 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C
Thalassemia

Interventions

DRUG: Peginterferon Alfa-2a and Ribavirin
DRUG: Ribavirin

Sponsor

Carelon Research

Collaborators

[object Object]